MA42380A - Anticorps se liant à tau - Google Patents

Anticorps se liant à tau

Info

Publication number
MA42380A
MA42380A MA042380A MA42380A MA42380A MA 42380 A MA42380 A MA 42380A MA 042380 A MA042380 A MA 042380A MA 42380 A MA42380 A MA 42380A MA 42380 A MA42380 A MA 42380A
Authority
MA
Morocco
Prior art keywords
tau
antibodies
bonding
antibodies bonding
Prior art date
Application number
MA042380A
Other languages
English (en)
Inventor
Terence Seward Baker
Jean-Philippe Courade
Patrick Downey
David Edward Ormonde Knight
Coello Georges Mairet-
Kerry Louise Tyson
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA42380A publication Critical patent/MA42380A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
MA042380A 2015-07-06 2016-07-05 Anticorps se liant à tau MA42380A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15175519 2015-07-06

Publications (1)

Publication Number Publication Date
MA42380A true MA42380A (fr) 2018-05-16

Family

ID=53524638

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41669A MA41669A1 (fr) 2015-07-06 2016-07-05 Anticorps se liant a tau
MA042380A MA42380A (fr) 2015-07-06 2016-07-05 Anticorps se liant à tau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41669A MA41669A1 (fr) 2015-07-06 2016-07-05 Anticorps se liant a tau

Country Status (22)

Country Link
US (4) US10344081B2 (fr)
EP (1) EP3319984B1 (fr)
JP (1) JP6937289B2 (fr)
KR (1) KR102742965B1 (fr)
CN (1) CN107849105B (fr)
AR (1) AR105266A1 (fr)
AU (1) AU2016289753C1 (fr)
CA (1) CA2991264C (fr)
CL (1) CL2018000042A1 (fr)
CO (1) CO2017012974A2 (fr)
EA (1) EA036821B1 (fr)
EC (1) ECSP18000844A (fr)
IL (1) IL256687B (fr)
MA (2) MA41669A1 (fr)
MX (1) MX2017015908A (fr)
PE (1) PE20180499A1 (fr)
PH (1) PH12017502180A1 (fr)
TN (1) TN2017000543A1 (fr)
TW (1) TWI748954B (fr)
UY (1) UY36774A (fr)
WO (1) WO2017005732A1 (fr)
ZA (1) ZA201708128B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (fr) 2013-03-13 2023-08-29 Prothena Biosciences Limited Immunotherapie contre tau
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
MA41670A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
CA3045294A1 (fr) 2016-12-07 2018-06-14 Genentech, Inc. Anticorps anti-tau et methodes d'utilisation
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
EP4491234A3 (fr) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer
WO2018148447A1 (fr) * 2017-02-08 2018-08-16 Adimab, Llc Domaines variables de chaînes lourdes d'anticorps ciblant le récepteur nkg2d
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
UA129617C2 (uk) 2017-10-16 2025-06-18 Еісаі Р Енд Д Менеджмент Ко., Лтд. Антитіло до тау та його застосування
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
US12509505B2 (en) 2018-12-13 2025-12-30 INSERM (Institute National de la Santé et de la Recherche Médicale) Anti Tau SVQIVYKPV epitope single domain antibody
CA3131531A1 (fr) 2019-03-03 2020-09-10 Prothena Biosciences Limited Anticorps reconnaissant la proteine tau
BR112022020410A2 (pt) * 2020-04-08 2023-01-03 Janssen Biotech Inc Anticorpos anti-phf-tau e usos dos mesmos
EP4146271A4 (fr) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et clec12a
US20230265175A1 (en) 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
EP4271708A1 (fr) * 2020-12-29 2023-11-08 Neurimmune AG Anticorps anti-tau humains
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (fr) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à la protéine tau
WO2025147472A1 (fr) * 2024-01-02 2025-07-10 Phanes Therapeutics, Inc. Anticorps anti-611-ctf p95her2 et leurs utilisations
WO2025196217A1 (fr) 2024-03-21 2025-09-25 UCB Biopharma SRL Traitement de tauopathies avec des anticorps se liant à la protéine tau

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
WO1993008302A1 (fr) 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Anticorps monoclonaux diriges contre la proteine tau associee aux microtubules
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
AU698383B2 (en) 1993-12-21 1998-10-29 Innogenetics N.V. Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications
ATE234324T1 (de) 1994-07-29 2003-03-15 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004253738A1 (en) 2003-07-01 2005-01-13 Ucb Pharma S.A. Modified antibody Fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
EP2500352A1 (fr) 2005-08-19 2012-09-19 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
CA2632822C (fr) 2005-12-12 2018-08-28 Ruth Greferath Anticorps monoclonaux specifiques beta 1-42 ayant des proprietes therapeutiques
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
WO2009120178A1 (fr) * 2008-03-26 2009-10-01 Epitomics, Inc. Anticorps dirigé contre le facteur de croissance de l'endothélium vasculaire
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
LT2334705T (lt) 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
WO2010144711A2 (fr) 2009-06-10 2010-12-16 New York University Ciblage immunologique de protéines tau pathologiques
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
IN2012DN00446A (fr) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
CA2826286C (fr) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Traitement de tauopathies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SG10201912964PA (en) 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
CN108034005B (zh) * 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
SI2776466T1 (sl) 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
DK2794654T3 (da) 2011-12-20 2019-08-05 Janssen Biotech Inc Anti-phf-tau-antistoffer og deres anvendelser
EP2834270B1 (fr) 2012-04-05 2019-10-30 AC Immune S.A. Anticorps tau humanisé
SG10201913370PA (en) 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
WO2014016737A1 (fr) 2012-07-24 2014-01-30 Pfizer Inc. Nouveaux anticorps monoclonaux de poulet dirigés contre la protéine tau phosphorylée humaine et leurs utilisations
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
BR112015014751A8 (pt) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
CA2902026C (fr) 2013-03-13 2023-08-29 Prothena Biosciences Limited Immunotherapie contre tau
US9598485B2 (en) 2013-03-15 2017-03-21 Ac Immune S.A. Anti-tau antibodies and methods of use
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
CA2874083C (fr) * 2014-12-05 2024-01-02 Universite Laval Polypeptides liant le tdp-43 utiles pour le traitement de maladies neurodegeneratives
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
MA41670A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها

Also Published As

Publication number Publication date
ZA201708128B (en) 2019-05-29
NZ737843A (en) 2024-05-31
IL256687A (en) 2018-03-29
EP3319984A1 (fr) 2018-05-16
IL256687B (en) 2022-02-01
US20210139574A1 (en) 2021-05-13
TWI748954B (zh) 2021-12-11
AU2016289753C1 (en) 2021-08-05
CA2991264A1 (fr) 2017-01-12
US20180194832A1 (en) 2018-07-12
MA41669A1 (fr) 2018-05-31
KR102742965B1 (ko) 2024-12-13
CN107849105B (zh) 2021-09-17
CN107849105A (zh) 2018-03-27
US11746145B2 (en) 2023-09-05
BR112017028101A2 (en) 2018-09-04
TN2017000543A1 (en) 2019-04-12
CL2018000042A1 (es) 2018-06-01
US10344081B2 (en) 2019-07-09
US20190375829A1 (en) 2019-12-12
MX2017015908A (es) 2018-03-15
PE20180499A1 (es) 2018-03-09
CO2017012974A2 (es) 2018-03-09
UY36774A (es) 2017-01-31
WO2017005732A1 (fr) 2017-01-12
AU2016289753B2 (en) 2020-11-26
CA2991264C (fr) 2023-10-10
JP2018519833A (ja) 2018-07-26
EP3319984B1 (fr) 2026-03-11
JP6937289B2 (ja) 2021-09-22
TW201713688A (zh) 2017-04-16
PH12017502180A1 (en) 2018-05-28
US10906966B2 (en) 2021-02-02
EA036821B1 (ru) 2020-12-23
EA201890169A1 (ru) 2018-10-31
AU2016289753A1 (en) 2017-12-14
US20230331833A1 (en) 2023-10-19
KR20180027566A (ko) 2018-03-14
AR105266A1 (es) 2017-09-20
ECSP18000844A (es) 2018-03-31

Similar Documents

Publication Publication Date Title
MA42380A (fr) Anticorps se liant à tau
MA42377A (fr) Anticorps se liant à tau
FR24C1056I2 (fr) Nouveaux anticorps anti-pd-l1
MA51734A (fr) Anticorps se liant à gprc5d
FR25C1022I1 (fr) Anticorps anti-pd-1
EP3512549A4 (fr) Anticorps se liant à cd3
EP3498840A4 (fr) Anticorps anti-lag-3
EP3423089A4 (fr) Anticorps anti-tigit
EP3334757A4 (fr) Anticorps anti-tigit
EP3334763A4 (fr) Nouveaux anticorps anti-pd-1
EP3297671A4 (fr) Anticorps anti-ror1
EP3334824A4 (fr) Anticorps anti-pd-1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3349787A4 (fr) Anticorps cd47 thérapeutiques
EP3307777A4 (fr) Nouveaux anticorps anti-pd-l1
MA53297A (fr) Anticorps anti-icos
MA52643A (fr) Anticorps se liant spécifiquement au tl1a
EP3492591A4 (fr) Anticorps anti-b7-h4
MA49289A (fr) Anticorps se liant à steap-1
EP3383915A4 (fr) Anticorps anti-pd-1
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3399992A4 (fr) Anticorps autoréticulants
IL263272A (en) Anti-coagulation factor xi antibodies
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
EP2949750A4 (fr) Peptide liant les anticorps